title: Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant.
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D064592:Autografts; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin